Human Serine protease 23 (PRSS23) ELISA Kit | AE25614HU

Human Serine protease 23 (PRSS23) ELISA Kit | AE25614HU | Gentaur UK, US & Europe Distribution

Species Reactivity: Human (Homo sapiens)

Abbreviation: PRSS23

Alternative Name: MGC5107; SIG13; SPUVE; ZSIG13; serine protease; umbilical endothelium

Application: ELISA

Range: 0.312-20 ng/mL

Sensitivity: 0.114 ng/mL

Intra-Assay: ≤6.5%

Inter-Assay: ≤9.2%

Recovery: 1, 02

Sample Type: Serum, Plasma, Other biological fluids

Detection Method: Sandwich

Analysis Method : Quantitive

Test Principale: This assay employs a two-site sandwich ELISA to quantitate PRSS23 in samples. An antibody specific for PRSS23 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyPRSS23 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for PRSS23 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of PRSS23 bound in the initial step. The color development is stopped and the intensity of the color is measured.

Product Overview: PRSS23 encodes a member of the trypsin family of serine proteases. Mouse studies found a decrease of mRNA levels after ovulation was induced. This gene seems to be highly conserved in vertebrates and may be an important ovarian protease. PRSS23 is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PRSS23 as well as pharmaceutical compositions comprising such compounds. The invention also provides PRSS23 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.

Stability: The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition. The loss rate was determined by accelerated thermal degradation test. Keep the kit at 37°C for 4 and 7 days, and compare O.D.values of the kit kept at 37°C with that of at recommended temperature. (referring from China Biological Products Standard, which was calculated by the Arrhenius equation. For ELISA kit, 4 days storage at 37°C can be considered as 6 months at 2 - 8°C, which means 7 days at 37°C equaling 12 months at 2 - 8°C) .